Resalis Therapeutics
Resalis Therapeutics is dedicated to developing RNA-based therapies that address the root causes of complex metabolic disorders. With expertise in non-coding RNA and lipid metabolism, the company is advancing RES-010, a promising therapy currently in Phase 1 clinical trials, targeting obesity and fatty liver disease. The company aims to offer safe, effective, and disease-modifying treatments, expanding its pipeline to include therapies for metabolic diseases with significant unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Resalis Therapeutics
Via Ettore de Sonnaz 19, 10121, Torino, Italy
Products
RES-010
An antisense oligonucleotide designed to target and inhibit miR-22, developed for treating obesity and metabolic associated fatty liver disease (MAFLD) and its progressive state, metabolic associated steatohepatitis (MASH).
RES-010
An antisense oligonucleotide designed to target and inhibit miR-22, developed for treating obesity and metabolic associated fatty liver disease (MAFLD) and its progressive state, metabolic associated steatohepatitis (MASH).
News & Updates
September 12, Copenhagen
October 11-13, Yokohama, Japan
November 4-6, Stockholm
October 6- 9, Montreal
April 28-30, Pisa, Italy
March 20-22, Basel
September 12, Copenhagen
October 11-13, Yokohama, Japan
November 4-6, Stockholm
October 6- 9, Montreal
April 28-30, Pisa, Italy
March 20-22, Basel